Current Issue

View Larger Image

Past Issues Adlink Subscription Visit Our Publisher

ADVERTISEMENT



Top Keywords




GENpoll: Nov 08, 2011

Cancer Vaccines

Will Biovest’s immunotherapy for follicular lymphoma, if approved, gain acceptance more quickly than Dendreon’s vaccine for prostate cancer?

Yes
 
  72.2%
No
 
  10.2%
Undecided
 
  17.6%

Suggest a Poll
« More Polls » « View Results »

Some have questioned whether issues with the launch of Dendreon’s prostate cancer vaccine, Provenge, will impact the market for other immunotherapies. A likely next-up autologous cancer vaccine is BioVest’s BiovaxID®, initially being developed for follicular lymphoma. The Provenge manufacturing process requires that cells are removed from the patient, treated in the laboratory, and then returned to the patient. For BiovaxID, hybridoma cells are used to express the lymphoma patient’s individual tumor idiotype. Details on their advantages can be found here. With regard to autologous manufacturing, Biovest’s president Samuel S. Duffey pointed out that the indolent nature of follicular lymphoma is such that the production time frames are not as limited as Dendreon’s. He says that Dendreon’s manufacturing and administration cycle impacts billing and reimbursement, which he doesn’t predict will happen with BiovaxID.

Related content

GEN News Highlights

MORE RELATED GEN NEWS HIGHLIGHTS

Insight & Intelligence™

MORE RELATED INSIGHT & INTELLIGENCE™

GEN Articles

MORE RELATED GEN ARTICLES

BLOG biotech

MORE RELATED BLOG BIOTECH

Webinars

MORE RELATED WEBINARS

GEN Podcasts

MORE RELATED GEN PODCASTS

Best of the Web

MORE RELATED BEST OF THE WEB

GEN Polls

MORE RELATED GEN POLLS

Subscription center

BACK TO TOP

GEN MAGAZINE

Genetic Engineering & Biotechnology News (GEN) has retained its position as the most widely read biotechnology publication around the globe since its launch in 1981. Published 21 times a year and with additional exclusive editorial content online, GEN's unique news and technology focus includes the entire bioproduct life cycle from early-stage R&D, to applied research including omics, biomarkers, as well as diagnostics, to bioprocessing and commercialization.

Subscribe
e-NEWSLETTERS

Add GEN to your Inbox! Subscribe today to our complimentary e-newsletters and stay abreast of the latest biotech news and trends. Click the magnifying glass icon next to a newsletter title to view a sample.
 

All fields are required
Email
Confirm Email
First Name
Last Name
Organization
E-Alert Format
 
 
  Sign Up

ADVERTISEMENT

GEN webinars

« View All Webinars »

ADVERTISEMENT

ADVERTISEMENT

GENpoll

Funding Early-Stage Companies

How much do you think newly established funds will succeed in helping startups?

Suggest a Poll
« More »     « View Results »     « Poll Archive »